Fukagawa Masafumi, Komaba Hirotaka, Hamano Takayuki
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan.
Scand J Clin Lab Invest Suppl. 2012;243:120-3. doi: 10.3109/00365513.2012.682882.
Vitamin D not only plays important roles in mineral metabolism, but also affects the risk of mortality and cardiovascular events. Since the kidney is the main organ that produces 1,25-dihydroxyvitamin D, active vitamin D sterols are widely used in patients with chronic kidney disease (CKD), especially those with secondary hyperparathyroidism. CKD patients also have higher risk of vitamin D deficiency, due to urinary loss associated with proteinuria and possible down-regulation of megalin in the proximal tubular cells. Accordingly, it is reasonable to supplement nutritional vitamin D in CKD patients with vitamin D deficiency. Although still unclear, it has been suggested that local 1α-hydroxylase activity plays more significant roles in CKD patients compared to those with normal kidney function. Future studies should examine whether correction of vitamin D deficiency, administration of active vitamin D, or both, provides survival benefits in patients with CKD.
维生素D不仅在矿物质代谢中发挥重要作用,还会影响死亡率和心血管事件的风险。由于肾脏是产生1,25-二羟基维生素D的主要器官,活性维生素D甾醇被广泛用于慢性肾脏病(CKD)患者,尤其是那些患有继发性甲状旁腺功能亢进的患者。CKD患者还存在维生素D缺乏的较高风险,这是由于蛋白尿导致的尿流失以及近端肾小管细胞中巨膜蛋白可能的下调。因此,对维生素D缺乏的CKD患者补充营养性维生素D是合理的。尽管仍不清楚,但有人提出,与肾功能正常的患者相比,局部1α-羟化酶活性在CKD患者中发挥着更重要的作用。未来的研究应探讨纠正维生素D缺乏、给予活性维生素D或两者兼施是否能为CKD患者带来生存益处。